Federal Register / Vol. 76, No. 53 / Friday, March 18, 2011 / Notices 14979 

enables wider use, and maintains NHSN 

to obtain scientifically valid clinical 

performance indices and benchmarks 

that promote healthcare quality and 

value at the facility, state, and national 

levels; (6) conducts applied research to 

identify and develop innovative 

methods to detect and monitor HAI and 

antimicrobial resistance; (7) conducts 

special studies and provides national 

estimates of targeted, healthcareassociated adverse events, antimicrobial 

use and resistance patterns, and the 

extent to which prevention and control 

safeguards are in use to protect at-risk 

patients across the spectrum of 

healthcare delivery sites; (8) uses NHSN 

and other data sources to conduct 

special studies and provide national 

estimates of targeted occupational 

illnesses and injuries among healthcare 

workers and the extent to which 

preventive safeguards are in use across 

the spectrum of healthcare delivery 

sites; and (9) leads CDC’s national 

adverse drug events surveillance 

activities and seeks to translate 

population-based surveillance data into 

evidence-based policies and targeted, 

innovative and collaborative 

interventions. 

Immunization Safety Office (CVLDE). 

(1) Assesses the safety of new and 

currently available vaccines received by 

children, adolescents and adults; (2) 

coordinates vaccine safety activities at 

CDC; (3) conducts public health 

surveillance to identify adverse events 

following immunization; (4) in 

collaboration with the Food and Drug 

Administration, coordinates and 

maintains the Vaccine Adverse Event 

Reporting System, a national reporting 

system that serves as an early-warning 

system to detect medical problems that 

may be related to vaccines; (5) 

coordinates and maintains the Vaccine 

Safety Datalink, a collaborative effort 

with managed care organizations, to 

assess adverse events following 

immunization; (6) administers the 

Clinical Immunization Safety 

Assessment network, a national network 

of medical research centers with 

expertise in immunization safety 

conducting clinical research on 

immunization-associated health risks; 

(7) participates in the Brighton 

Collaboration, an international 

collaboration of scientists from around 

the world working to develop, evaluate, 

and disseminate globally accepted 

standard case definitions for adverse 

events following immunization and 

guidelines for collection, analysis, and 

presentation of vaccine safety data; and 

(8) works with other federal agencies, 

state governments, and other public and 

private organizations to assess and 

promote the safety of vaccines. 

Dated: March 10, 2011. 

James D. Seligman, 

Acting Chief Operating Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2011–6179 Filed 3–17–11; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Muscular Dystrophy Coordinating 

Committee (MDCC). 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

inform the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Date: April 20, 2011. 

Time: 8 a.m. to 4:30 p.m. 

Agenda: The 2011 meeting of the MDCC 

will review Federal agency activities in the 

muscular dystrophies, brief participants on 

the NIH grant database, NIH RePORTER, 

discuss therapy development resources at the 

NIH, and review joint NIH/FDA activities 

and initiatives in rare diseases. The MDCC 

will also discuss new opportunities in 

therapy development based upon a 

representative example of a new mechanistic 

finding and the lessons learned in current 

drug development programs. A panel will 

review and discuss the challenges of 

conducting clinical trials in the muscular 

dystrophies. 

An agenda will be posted prior to the 

meeting on the MDCC Web site: http:// 

www.ninds.nih.gov/find_people/groups/ 

mdcc/index.htm. 

Place: Hilton Rockville Hotel & Executive 

Meeting Center, 1750 Rockville Pike, 

Rockville, Maryland 20852–1699. 

Contact Person: John D. Porter, PhD, 

Executive Secretary, Muscular Dystrophy 

Coordinating Committee, National Institute 

of Neurological Disorders and Stroke, NIH, 

6001 Executive Boulevard, NSC 2172, 

Bethesda, MD 20892, (301) 496–5739, 

porterjo@ninds.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

their statement to the Contact Person listed 

on this notice. The statement should include 

the name, address, telephone number and 

when applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: March 11, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–6453 Filed 3–17–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Open Meeting Notice 

Notice is hereby given that the 

National Institutes of Health (NIH), 

Department of Health and Human 

Services, will hold a scientific 

workshop. 

Title: ‘‘State of the Knowledge 

Workshop on Myalgic 

Encephalomyelitis/Chronic Fatigue 

Syndrome (ME/CFS) Research’’. 

Dates: April 7–8, 2011. 

Time: 8 a.m. to 5 p.m. 

Place: Building 31, Conference Rooms 

6C8/9/10, NIH campus, Bethesda, 

Maryland. 

Purpose of the Meeting: This 

workshop will bring together subject 

matter experts who will discuss 

multiple aspects of ME/CFS, including 

epidemiology, etiology, 

pathophysiology, diagnosis, and 

treatment. The workshop panelists will 

identify gaps in knowledge and 

opportunities for advancing biomedical 

research. 

This workshop is open to the public. 

Please note that attendance is limited. 

We encourage registration for those 

attending in person (see Web address 

below). For those unable to attend, the 

workshop will be available via NIH 

VideoCasting (http://videocast.nih.gov/) 

both during and after the event. 

Individuals with disabilities who 

need reasonable accommodation should 

indicate their needs on registration or 

contact Infinity Conference Group by 

telephone at 703–925–9455, ext. 0, or email at icg@infinityconferences.com. 

For more information including an 

agenda, registration, and visitor 

information, please visit the workshop 

Web site: https:// 

www.infinityconferences.com/ 

InfiniBase/Templates/157557/ 

Index.htm. 

Contact Person: Dennis Mangan, PhD; 

Chair, Trans-NIH ME/CFS Research 

Working Group, Office of Research on 


Emcdonald on DSK2BSOYB1PROD with NOTICES